Knocking Down Low Molecular Weight Protein Tyrosine Phosphatase (LMW-PTP) Reverts Chemoresistance through Inactivation of Src and Bcr-Abl Proteins

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Ferreira, Paula A ^a   Ruela de Sousa, Roberta R ^a,b   Queiroz, Karla C S ^b,c   Souza, Ana Carolina S ^d   Milani, Renato ^a   Pilli, Ronaldo Aloise ^a   Peppelenbosch, Maikel P ^c   Hertog, Jeroen den ^e   Ferreira, Carmen V ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSIDADE FEDERAL DO ABC   (Brazil)

^e HUBRECHT INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE KINASE; TUMOR PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; MULTIDRUG RESISTANCE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION;

ANTINEOPLASTIC AGENTS; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; K562 CELLS; MOLECULAR WEIGHT; P-GLYCOPROTEIN; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASES; SRC-FAMILY KINASES;

EID: 84866045402     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044312     Document Type: Article

References (23)

1. Dean M, Fojo T, Bates S, (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284 doi:10.1038/nrc1590.
2. Higgins CF, (2007) Multiple molecular mechanisms for multidrug resistance transporters. Nature 446: 749-757 doi:10.1038/nature05630.
3. Ruela de Sousa RR, Queiroz KCS, Peppelenbosch MP, Fuhler GM, (2010) Reversible phosphorylation in haematological malignancies: Potential role for protein tyrosine phosphatases in treatment? Biochimica et Biophysica Acta (BBA)- Reviews on Cancer 1806: 287-303 doi:10.1016/j.bbcan.2010.07.007.
4. Souza ACS, Azoubel S, Queiroz KCS, Peppelenbosch MP, Ferreira CV, (2009) From immune response to cancer: a spot on the low molecular weight protein tyrosine phosphatase. Cell Mol Life Sci 66: 1140-1153 doi:10.1007/s00018-008-8501-8.
5. Chiarugi P, Taddei ML, Schiavone N, Papucci L, Giannoni E, et al. (2004) LMW-PTP is a positive regulator of tumor onset and growth. Oncogene 23: 3905-3914 doi:10.1038/sj.onc.1207508.
6. Chiarugi P, Cirri P, Raugei G, Camici G, Dolfi F, et al. (1995) PDGF receptor as a specific in vivo target for low M(r) phosphotyrosine protein phosphatase. FEBS Letters 372: 49-53.
7. Lee JK, Edderkaoui M, Truong P, Ohno I, Jang K-T, et al. (2007) NADPH oxidase promotes pancreatic cancer cell survival via inhibiting JAK2 dephosphorylation by tyrosine phosphatases. Gastroenterology 133: 1637-1648 doi:10.1053/j.gastro.2007.08.022.
8. Rigacci S, Talini D, Berti A, (2003) LMW-PTP associates and dephosphorylates STAT5 interacting with its C-terminal domain. Biochemical and Biophysical Research Communications 312: 360-366.
9. Kikawa KD, Vidale DR, Van Etten RL, Kinch MS, (2002) Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J Biol Chem 277: 39274-39279 doi:10.1074/jbc.M207127200.
10. Raugei G, Ramponi G, Chiarugi P, (2002) Low molecular weight protein tyrosine phosphatases: small, but smart. Cell Mol Life Sci 59: 941-949.
11. Rumjanek VM, Trindade GS, Wagner-Souza K, de-Oliveira MC, Marques-Santos LF, et al. (2001) Multidrug resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1. An Acad Bras Cienc 73: 57-69.
12. Renzi NL, Stellar SM, Ng KT, (1983) Gas chromatographic assay of codeine in human plasma utilizing nitrogen-selective detection. J Chromatogr 278: 179-184.
13. Kondo Y, Kanzawa T, Sawaya R, Kondo S, (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5: 726-734 doi:10.1038/nrc1692.
14. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM, (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234 doi:10.1038/nrd1984.
15. Malentacchi F, Marzocchini R, Gelmini S, Orlando C, Serio M, et al. (2005) Up-regulated expression of low molecular weight protein tyrosine phosphatases in different human cancers. Biochemical and Biophysical Research Communications 334: 875-883 doi:10.1016/j.bbrc.2005.06.176.
16. Huanwen W, Zhiyong L, Xiaohua S, Xinyu R, Kai W, et al. (2009) Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer 8: 125 doi:10.1186/1476-4598-8-125.
17. Mahon F, Hayette S, Lagarde V, Belloc F (2008) Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression. Cancer Research.
18. Chen S-Y, Moroi Y, Urabe K, Takeuchi S, Kido M, et al. (2008) Concordant overexpression of p-FAK and p-ERK1/2 in extramammary Paget's disease. Arch Dermatol Res 300: 195-201 doi:10.1007/s00403-008-0829-2.
19. Ren M, Qin H, Ren R, Tidwell J, Cowell JK, (2011) Src Activation Plays an Important Key Role in Lymphomagenesis Induced by FGFR1 Fusion Kinases. Cancer Research 71: 7312-7322 doi:10.1158/0008-5472.CAN-11-1109.
20. Boehrer S, Galluzzi L, Lainey E, Bouteloup C, Tailler M, et al. (2011) Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia. Cell Cycle 10: 3168-3175.
21. Finn RS, (2008) Targeting Src in breast cancer. Annals of Oncology 19: 1379-1386 doi:10.1093/annonc/mdn291.
22. Alvarez RH, Kantarjian HM, Cortes JE, (2006) The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 107: 1918-1929 doi:10.1002/cncr.22215.
23. Daley G, Van Etten R (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science.